Preferred Dosing Schedule Pledged by HCV Drug Candidate
Share
Follow Us
The Editors at Hepatitis Central
March 25, 2010
Zalbin is a Hepatitis C drug in development that could lead to the highly desired monthly or bi-monthly dosing.
Human Genome Sciences reports hepatitis drug study
The Associated Press March 24, 2010
ROCKVILLE, Md.
Human Genome Sciences Inc. said Wednesday a midstage study of the potential hepatitis C treatment Zalbin showed a monthly dose of the drug candidate could be as effective as a weekly dose of the standard treatment.
Continue reading this entire article:
http://www.businessweek.com/ap/financialnews/D9EL00D82.htm
